6981 - 6990 of 7915 Results
Title
Year
-
RESTRICTEDTitle: Resistance of naturally secreted α‐synuclein to proteolysisJournal Name: The FASEB JournalPublisher: WileyVol: 28Issue #: 7Start Page: 3146End Page: 3158Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1096/fj.13-245852Citation Count: 19
-
OPENTitle: Essential Tremor in the Elderly and Risk for DementiaJournal Name: Journal of Neurodegenerative DiseasesPublisher: Hindawi LimitedVol: 2014Issue #:Start Page: 1End Page: 5Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2014/328765Best OA location URL: https://downloads.hindawi.com/archive/2014/328765.pdfCitation Count: 22
- Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)2014RESTRICTEDTitle: Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)Journal Name:Publisher:Vol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier:Citation Count: 0
- Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)2014RESTRICTEDTitle: Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 82Issue #: 10_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.82.10_supplement.p1.016Citation Count: 0
- The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)2014RESTRICTEDTitle: The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)Journal Name:Publisher:Vol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier:Citation Count: 2
- The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)2014RESTRICTEDTitle: The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 82Issue #: 10_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.82.10_supplement.p4.043Citation Count: 4
-
OPENTitle: Evaluation of mild cognitive impairment subtypes in Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 29Issue #: 6Start Page: 756End Page: 764Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.25875Best OA location URL: https://europepmc.org/articles/pmc4013249?pdf=renderCitation Count: 55
-
RESTRICTEDTitle: Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?Journal Name: Journal of Comparative NeurologyPublisher: WileyVol: 522Issue #: 12Start Page: 2802End Page: 2816Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/cne.23577Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cne.23577Citation Count: 46
- Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits2014OPENTitle: Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficitsJournal Name: Frontiers in Systems NeurosciencePublisher: Frontiers Media SAVol: 8Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnsys.2014.00045Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnsys.2014.00045/pdfCitation Count: 96
- Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease2014OPENTitle: Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's diseaseJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 10Start Page: 2329End Page: 2346Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2014.03.032Best OA location URL: https://europepmc.org/articles/pmc4892899?pdf=renderCitation Count: 63